Clinical trialNCT04560322RecruitingPhase 2Interventional

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

SponsorMassachusetts General HospitalEnrollment40Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: * obinutuzumab * venetoclax * acalabrutinib

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jacob D Soumerai, MD
Massachusetts General Hospital
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Jon Arnason, MD
Not, yet, recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Matthew S Davids, MD
Not, yet, recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Jacob D Soumerai, MD →
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Acalabrutinib →Obinutuzumab →Venetoclax →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Oct 2020
Primary completion: 1 Mar 2028
Completion: 1 Mar 2029
Last update posted: 13 Apr 2026
Registered enrollment: 40
Registry id: NCT04560322

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.